Geron Corp - Company Profile
Powered by
All the data and insights you need on Geron Corp in one report.
- Save hours of research time and resources with
our up-to-date Geron Corp Strategy Report
- Understand Geron Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Geron Corp (Geron) is a clinical stage biopharmaceutical company, which undertakes the development of imetelstat, a telomerase inhibitor as first-in-class therapies for cancer. The company’s lead product candidate: Imetelstat, product pipeline, and focus on R&D are its strengths, while operating loss carryforward could be an area for concern. The company could benefit from rare and orphan drugs, rising healthcare expenditure in the US and positive results from clinical trials. Nevertheless, its performance could be affected by government regulations, uncertain R&D outcomes and competitive environment in the industry.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer